医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NEW YORK

OneMedPlace today announced the final program for its “China Forum III” that will be held at the Sir Francis Drake Hotel, San Francisco, from 1-4 pm on January 7, 2013. This session has become an annual gathering of leading U.S., European, and Chinese investors and executives who are active in the rapidly developing healthcare marketplace in China.

“We are very pleased to once again assemble some of the most influential and prominent investors and executives to discuss how Western technologies can be applied to the rapidly growing Chinese healthcare market,” said Brett Johnson, CEO of OneMedPlace, organizer of the China Forum. “I would like to thank my co-chair Tony Zhang, immediate past Chairman of BayHelix, an organization of Chinese life science business leaders, who has helped assemble our panel.”

“The China Forum has become a focal point for people doing business in China or wanting to participate in the most vibrant healthcare market during the JP Morgan conference week. It has been a very effective way to connect with the industry leaders directly,” said Mr. Zhang.

The event will open with remarks from Bin Li, Managing Director and Senior Research Analyst for China Healthcare, Morgan Stanley Research. Dr. Li will offer an overview of the Chinese healthcare sector and provide insight about the major challenges and opportunities for investors and growth companies looking to capitalize on China’s growing healthcare sector.

Three separate panels reviewing and discussing actual case studies of transactions involving Western technology and Chinese investors and management will follow. “We will get perspectives of those engaged in these deals about what works and what doesn’t. The program was created to give insight to Western companies that are serious about China and the huge opportunity that exists there,” said Johnson.

The session will also include remarks from Ms. Yuwen Liu, the CEO of BioBay in Suzhou Industrial Park, who will provide her perspectives about opportunities for Western companies in China.

The Program will focus on specific case studies of joint ventures in China, successful and otherwise. Assisting in the programming are Philip Groves, CEO of DAC Management, an alternative management fund active in China; Landon Lack, CEO of China MedConnect; and David Chen, Managing Director of BFC Group. Each of these gentlemen has participated in numerous transactions involved in medical technology firms.

Case situations will also be provided by other conference panelists who include: Dr. Jimmy Zhang, Managing Director, MSD Early Investments–Greater China at Merck & Co. and Chairman of BayHelix; Dr. Jay Dong, General Manager, Asia Pacific Region, Cell Signaling Technology (CST), Inc., Vice Chairman of BayHelix; Dr. May Wang, SVP, Business Development, Hutchsion MediPharma; Dr. Mike Liu, Head, Business Development, Jiangsu Hengrui Medicine; Dr. Alan Paau, Vice Provost and Executive Director, Cornell Center for Technology Enterprise & Commercialization, Cornell University; Dr. Jie D’Elia, Corporate Vice President of Business Development and Corporate Communications, President of Simcere of America; Dr. James Tong, CFO, Chief Business & Development Officer and Director, Tianyin Pharmaceuticals; Mark Xu, General Manager, Trout Group at Shanghai. This program is designed to provide guidance for the emerging growth companies in healthcare and life science companies that attend the OneMedForum and are part of the OneMedPlace Global Database.

For more information visit the conference website. www.onemedforum.com